Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: The measurement of parathyroid hormone(PTH) in situ (PTHis) by fine-needle aspiration (FNA) has been proposed as a tool to preoperatively help localize parathyroid glands detected on ultrasound. However, the accuracy of PTHis is highly variable according to the few available studies.
Aim: We aimed to develop and validate the PTHis procedure and assessed the performance of PTHis in a large series of patients with hyperparathyroidism and/or undetermined cervical lesions.
Patients And Methods: The technique set-up consisted of PTHis measurement in thyroid samples from patients with thyroid nodules and patients with high circulating PTH levels (tertiary hyperparathyroidism). Consecutive patients were recruited at one tertiary referral centre from 2017 to 2020 and submitted to ultrasound-guided FNA-PTHis determination.
Results: During the method set-up, we obtained undetectable PTHis levels in all non-parathyroid tissues after sample dilutions. PTHis was higher in patients with hyperparathyroidism (n = 145; 1817 ± 3739 ng/L; range: <4.6-31 140) than in those with thyroid or undetermined cervical lesions (n= 34; <4.6 ng/mL; P < 0.0001). When evaluating PTHis performance in histologically proven samples (158 lesions from 121 patients), PTHis was detectable in 85/97 parathyroid lesions (87%; range: 22-31;140 ng/L) and undetectable in all non-parathyroid lesions (n = 61; P < 0.0001). The specificity and positive predictive value were 100%, and the sensitivity was 87.6%. False-negative lesions (n= 12) were smaller (9.4 ± 5.9 mm) and more often consisted of hyperplasias (75%) than true-positive lesions (16.1 ± 8.4 mm and 33%, P = 0.009 and P = 0.0089, respectively). The method was safe and well tolerated. Four educational cases are also provided.
Conclusions: PTHis determination is a safe and well-tolerated procedure that enhances the specificity of ultrasound-detected lesions. If accurately set-up, it confirms the parathyroid origin of uncharacterized cervical lesions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1530/EJE-21-1249 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and Laboratory Predictors for the Development of Heart Valve Diseases in Chronic Kidney Disease: A Systematic Review.
Arq Bras Cardiol
September 2025
Escola Bahiana de Medicina e Saúde Pública, Salvador, BA - Brasil.
Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.
Objective: To determine the risk factors for valvular calcification in patients with CKD.
Estimated fracture risk in osteopenic patients with primary hyperparathyroidism.
Endocrine
September 2025
Otorhinolaryngology, Head and Neck Surgery, Candiolo Cancer Institute, FPO-IRCCS Turin, Turin, Italy.
Background: While osteoporosis in primary hyperparathyroidism (PHPT) is widely studied, PHPT patients with osteopenia remain less characterized. This study aimed to evaluate the prevalence, biochemical features, and estimated fracture risk of osteopenic PHPT patients in a real-life cohort.
Methods: We retrospectively analyzed a consecutive series of PHPT patients with available densitometric data at three sites.
[Tc]Tc-Sestamibi/[Tc]NaTcO Subtraction SPECT of Parathyroid Glands Using Analysis of Principal Components.
J Nucl Med Technol
September 2025
Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and the General University Hospital in Prague, Prague, Czech Republic;
The aim of the study was to validate a new method for semiautomatic subtraction of [Tc]Tc-sestamibi and [Tc]NaTcO SPECT 3-dimensional datasets using principal component analysis (PCA) against the results of parathyroid surgery and to compare its performance with an interactive method for visual comparison of images. We also sought to identify factors that affect the accuracy of lesion detection using the two methods. Scintigraphic data from [Tc]Tc-sestamibi and [Tc]NaTcO SPECT were analyzed using semiautomatic subtraction of the 2 registered datasets based on PCA applied to the region of interest including the thyroid and an interactive method for visual comparison of the 2 image datasets.
View Article and Find Full Text PDFHyperparathyroidism Secondary to Burosumab Treatment.
Cureus
August 2025
Medicine, Western University of Health Sciences, Pomona, USA.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome of abnormal phosphorus metabolism caused by increased secretion of fibroblast growth factor 23 (FGF23) by small mesenchymal tumors. In this article, we reported a patient with chronic refractory hypophosphatemia due to TIO who is treated with burosumab, a monoclonal antibody that targets and blocks the activity of FGF23. Treatment with burosumab led to the resolution of his refractory hypophosphatemia, but this was complicated by the development of secondary hyperparathyroidism.
View Article and Find Full Text PDFA presentation of brown tumor in a patient with parathyroid adenoma and end-stage renal disease: A case report.
Medicine (Baltimore)
September 2025
Department of Internal Medicine, Lahore General Hospital, Lahore, Punjab, Pakistan.
Rationale: Brown tumor (osteitis fibrosa cystica) is a benign bone lesion associated with hyperparathyroidism that can affect multiple bones in patients with end-stage renal disease (ESRD).
Patient Concerns: We present the case of a 32-year-old female with ESRD on maintenance hemodialysis who experienced body aches, muscle weakness, constipation, and mood swings for 3 months.
Diagnoses: Initial tests revealed elevated parathyroid hormone (PTH), serum calcium, and phosphorus levels.